International educational Congress
(ROAIA – OAA) in memory of Geraldine O'Sallivan.
III Congress
of Russian Obstetrical Anaesthesiologists and Intensivists Association
arfpoint.com
ROAIA

Partners


SPONSORS


Generium

Generium

GENERIUM is the leading Russian biopharmaceutical company.
Our company develops and manufactures pharmaceutical
products for the treatment of orphan diseases, cancer, multiple
sclerosis, growth hormone deficiency, myocardial infarction and
strokes as well as tuberculosis diagnostic test.
Generium consists of a high-end R&D center and a fully integrated manufacturing plant.
In our R&D center consisting of 5,000 sq. m. of labs, biopharmaceuticals and cell-basedtechnologies
are developed up to the stage of industrial application.
Our manufacturing plant is equipped to the highest levels and operates according to Russian and
international GMP standards.
Today, seven pharmaceutical products are already available for patients in Russia and CIS countries.
These are recombinant Factors VII, VIII and IX for haemophilia treatment, interferon-beta-1b — for
multiple sclerosis and innovative skin test for TB detection.
Generium is the only company in the world, which produces three recombinant coagulation factors
(FVII, FVIII and FIX).
In 2014, our skin test for TB detection, Diaskintest, earned the international award Prix Galien for
achievements in biotechnology.
There are more than 40 innovative products in the pipeline, including enzymes, monoclonal antibodies
and cell-based therapeutic products. More than half of them have no equivalents in the world.
Our R&D park is located 120 km away from Moscow, where our strategic partners operate as well.

 

 


Alexion Pharmaceuticals

Alexion Pharmaceuticals

ALExION is a global biopharmaceutical company focused on
developing and delivering life-transforming therapies for patients
with devastating and rare diseases. Alexion’s approximately
3,000 employees around the world serve patients in 50 countries.
Alexion developed Soliris® (eculizumab), the world’s first
approved terminal complement inhibitor, from the laboratory through commercialization.
Today, Soliris is approved in nearly 50 countries for the treatment of patients with paroxysmal
nocturnal hemoglobinuria (PNH) and in more than 40 countries for the treatment of patients with
atypical hemolytic uremic syndrome (aHUS) — two life-threatening, ultra-rare disorders caused by
uncontrolled complement activation.
Soliris has received a number of the pharmaceutical industry’s highest honors for innovation,
including the Prix Galien USA Award in 2008 for the best Biotech product and the Prix Galien France
Award in 2009 in the category of Drugs for Rare Diseases.
Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies for
patients with life-threatening and ultra-rare disorders, Strensiq® (asfotase alfa) to treat patients
with hypophosphatasia (HPP) and Kanuma™ (sebelipase alfa) to treat patients with lysosomal acid
lipase deficiency (LAL-D).
Alexion Pharma, LLC
Country of origin: USA
Address: 143421 Moscow region, Krasnogorskiy area, Business Centre “Riga Land”,
building 5, floor 2
Tel.:+7 (495) 280 17 01
Email: alexion.russia@alexion.ru
Website: www.alxn.com

 

 


Pfizer

Pfizer

Pfizer: Working together for a healthier world
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-
known consumer health care products.
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases of our time. Consistent
with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we
collaborate with health care providers, governments and healthcare organizations to support and
expand access to reliable, affordable health care around the world.
For more than 160 years, Pfizer is working to make a difference for all who rely on us.
To learn more, please visit us at www.pfizer.com and www.pfizer.ru

 

 


Aspen

Aspen

Aspen Company – is an international company which produces
original and generic pharmaceutical products on 23 production
areas.
• Our goal is to produce high-quality medicines with affordable prices, and thereby share our values
with each patient. The combination of high quality and affordable prices is exactly what Aspen is
famous for all around the world.
• Aspen is a company with a long history, which originated more than 160 years ago. Today, the
company is already selling its products in more than 150 countries worldwide.
• Aspen began their journey through building a successful business on the African continent,
occupying leading positions on the market. Aspen managed to repeat its first achievements in
developed European markets, as well as in Australia, where the company has a fourth position.
• We have a goal to become the fastest growing company in the world, which produces and supplies
products, which meet the needs of healthcare and society.
• Aspen entry into the European market in 2009 started with the acquisition of the GSK cancer and
anti-thrombotic portfolio as well as three MSD products with production sites in Germany, France
and the Netherlands.
• In 2014, Aspen entered the pharmaceutical market in Russia and CIS countries.
We supply Russia and CIS with products which were manufactured in Europe.
• Aspen antithrombotic portfolio includes the leading products in Russia and the rest of the world
- Fraksiparin and Arixtra. We are fully focused on our goal - to ensure the supply of high quality
products with a fair value for our partners and patients.
Contacts:
123112, Moscow, Business Center «Imperia Tower»
Presnenskaya Embankment, 6/2 ,
Tel. : +7 (495) 969 20 51 , +7 (495) 969 20 53
www.aspenpharma.eu

 

 


POLYSAN

POLYSAN

Scientific Technological Pharmaceutical Firm
«POLYSAN», Ltd. was founded in 1992. The scope of the Firm
activities is the development and implementation of innovative
drugs into medical practice. STPF «POLYSAN», Ltd. is a
manufacturer of four original medicines: Cycloferon, Сytoflavin,
Reamberin and Remaxol. The «POLYSAN» specialists continue working on the development of
new original drugs. Eight of them will get to the pharmaceutical market in the nearest future. The
«POLYSAN» was awarded twice with the Prize of the Government of the Russian Federation for the
Distinguished Achievements in the Field of Science and Technology, with «Golden Mercury» Award
for Business, with the Prize of the St.Petersburg Administration for Quality. The «POLYSAN» has
the pharmaceutical plant, located in St.Petersburg and certified by the EU GMP Certificate. Currently,
STPF «POLYSAN», Ltd. is completing the construction of the 3nd stage of the pharmaceutical plant.
«Scientific Technological Pharmaceutical Firm «POLYSAN» Ltd.
Lit A, Building 2, 72 Salova Str., Saint-Petersburg, 192102, Russia
Tel.: +7 812 7121379
Fax: +7 812 7108225
E-mail: ovd@polysan.ru
www.polysan-ru.com

 

 


Lancet

Lancet

LANCET specialization is to provide Russian healthcare centers
with a complex of innovative pharmaceuticals, high-technology
equipment and high-quality disposables.
Lancet today:
- Our operations area – all Russia
- #3 hospital distributor in Russia
- 6 priority areas
• Contrast Media (CT, MRI)
• Antithrombotic therapy
• Pulmonology
• Anesthesiology & Intensive Care
• Oncology
• Rare diseases
- “Full Supply” concept approach: combination of pharmaceuticals / equipment / disposables for
various sectors of the Russian medicine, ranging from diagnostics and treatment at the hospital
stage to ensuring availability of quality medical products to reimbursement system throughout
Russia.
- Contracts with 140+ pharmaceutical companies
- 1700+ customers
- 8000+ items in price-list

 

 


Alfasigma

Alfasigma

Alfasigma’s roots are firmly planted in Italy where its historic
premises are located, the research centres and the production
plants, but its branches stretch out to a large part of the world
with its network of associate and subsidiary companies on five
continents.
It is a vast constellation that ensures Alfasigma has the people and the resources to produce and
distribute medicines for a broad variety of therapeutic areas ranging from prescription medicines
to self-medication, many of which are the outcome of research begun in the early nineteen sixties.
Alfasigma takes care of people and their health problems in full respect of ethical values and to strive
for a better world.
Drugs for the treatment of the cardiovascular system - the second most important therapeutic area
for the Alfasigma. The company has three main drugs: sulodexide, (in Russia as Vessel Due F®
brand) and parnaparin - low molecular weight heparin for the prevention and treatment of deep vein
thrombosis (in Russia registered as Fluxum® brand) and Neoton (an exogenous phosphocreatine
with cardioprotective effect ). All these products are the results of your development company.

 

 


Shire

Shire

Shire is the global leader in serving patients with rare diseases.
We strive to develop best-in-class therapies across a core of
rare disease areas including hematology, immunology, genetic
diseases, neuroscience, and internal medicine with growing
therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach
patients in more than 100 countries who are struggling to live their lives to the fullest.
We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve
people’s lives with medicines that have a meaningful impact on patients and all who support them
on their journey.
119021, Russia, Moscow
11/1, Timura Frunze Street
Тel.: +7 495 787 04 77
Fax: +7 495 787 04 78

 

 


Fresenius Kabi

Fresenius Kabi

Fresenius Kabi is a part of German health care group Fresenius
SE & Co. KGaA - a worldwide leader that specializes in lifesaving
medicines and technologies for infusion, transfusion and clinical
nutrition. Our products and services are used to help care for
critically and chronically ill patients.
Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and
clinical nutrition products as well as the medical devices for administering these products. Within
transfusion technologies, we offer products for collection and processing of blood components
and for therapeutic treatment of patient blood by apheresis systems. In the field of biosimilars, we
develop products with a focus on oncology and autoimmune diseases. Also Fresenius Kabi offers
products for the therapy and care of patients with CKD.
Fresenius Kabi LLC
Leningradsky prospect 37 bld. 9
125167 Moscow, Russian Federation
T: + 7 (495) 988-45-78
www.fresenius-kabi.ru
www.fresenius-kabi.com

 

 


MirManekenov.ru

MirManekenov.ru

MirManekenov.ru is one of the largest suppliers of training equipment for medical simulation. Our company has the widest assortment of goods, ranging from anatomical models to the most advanced wireless mobile remote mannequins. MirManekenov.ru is the only supplier of simulation equipment among CIS countries, in which all prices free 24 hours providing You with total transparency and the lowest price.

127322, Moscow, Milashenkova st., 16, pom. V
+7 495 639-85-72
info@mirmanekenov.ru
www.mirmanekenov.ru

 

 


B. Braun

B. Braun

B. Braun Melsungen AG is one of the world’s leading providers
and manufacturers of healthcare solutions with a tradition going
back more than 175 years.
The company offers fully staffed products and services for hospital
product ranges, surgery and convalescent care.
We offer:
- IV fluids, injectable drugs, clinical nutrition, medical devices and automated infusion systems for
hospital care in ICU, obstetrics and neonatology;
- Surgical equipment and tools
- Skin and wound management, ostomy care solutions, the full range of fluids for hygienic and
surgical processing of hands, disinfection of tools and surfaces
Head office B. Braun Medical - Russia
197101, St. Petersburg, Bolshoy prospect Petrogradskoi storony, 59
Tel. (812)320 40 04, fax (812)320 50 71
Е-mail: office.spb.ru@bbraun.com, web-site: www.bbraun.ru

 

 


MEDIPAL-ONKO LLC

MEDIPAL-ONKO LLC

 MEDIPAL-ONKO LLC
Established in 1994, MEDIPAL-ONKO is one of the leading Russian
distributor in the field of orphan and rare diseases.
For over 20 years of successful development the company has
acquired a unique knowledge and practical experience in the
Russian market in the area of the healthcare and social security.
Our strategic efforts are focused on creating product portfolio that includes innovative, high-
biotechnological and vital products.
The company has extensive experience in the field of oncology, rare hereditary diseases and other
life important nosologies providing us an advantage over competing pharmaceutical companies in
these segments.
47, Varshavskoe sh., bld. 4 Moscow, 115230, Russia
Тel.: +7 (495) 662 84 94
Fax: +7 (495) 662 84 95
e-mail: public@medipal-onko.ru
www.medipal-onko.ru

 

 

 

 

 

 


INFORMATION PARTNERS


Expomap

Expomap

 

 


IVRACH.COM

IVRACH.COM

 

 


Medical portal Medego.ru

Medical portal Medego.ru

 

 


Сообщество «Врачи РФ»

Сообщество «Врачи РФ»

 

 


Медицинский образовательный сайт социальная сеть для врачей

Медицинский образовательный сайт социальная сеть для врачей

 

 


Портал «Все науки»

Портал «Все науки»

 

 


Медицинский портал YellMed

Медицинский портал YellMed

 

 


Журнал Международной медицины

Журнал Международной медицины

 

 


Конференции.ru - информационная поддержка научных мероприятий

Конференции.ru - информационная поддержка научных мероприятий

 

 


critical.ru

critical.ru

 

 


«Consilium Medicum»

«Consilium Medicum»

 

 

 

 


Журнал «Медицина и здоровье»

Журнал «Медицина и здоровье»

 

 


«Неотложная медицина» серии «Медицинский алфавит»

«Неотложная медицина» серии «Медицинский алфавит»

 

 


Агентство медицинской информации «Медфорум»

Агентство медицинской информации «Медфорум»

 

 


ОМСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ

ОМСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ

 

 

 

 

 


Актион-МЦФЭР [ожидает перевода]

Актион-МЦФЭР [ожидает перевода]

 

 


Издательский дом «ПРАКТИЧЕСКАЯ МЕДИЦИНА»

Издательский дом «ПРАКТИЧЕСКАЯ МЕДИЦИНА»